(lp0
S'Allianz Asset Management AG Increases Stake in SciClone Pharmaceuticals, Inc ... Chaffey Breeze - 15 hours ago SciClone Pharmaceuticals logo Allianz Asset Management AG boosted its position in SciClone Pharmaceuticals, Inc.  by 25.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.Stock Returns: Supernus Pharmaceuticals Inc  is Beating SciClone ... - CML NewsSciclone Pharmaceuticals Inc  Files Form 4 Insider Selling : Lan Xie ... - Energy Index'
p1
aS'SciClone Pharmaceuticals: Beyond The Death Of A Sales Process Seeking Alpha - Feb 2, 2017 SciClone Pharmaceuticals  is a revenue-generating pharmaceutical company with a portfolio of HBV/HCV, oncology, anti-infection and cardiovascular drug candidates.'
p2
aS"Why SciClone Pharmaceuticals, Inc. Is Surging Higher Motley Fool - Mar 12, 2015 Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis."
p3
aS'SciClone Pharmaceuticals Inc. MarketWatch - Oct 28, 2009 Check out the returns on our 8 Lazy Portfolios that are made up of low-cost buy-and-hold index funds.  How to create your own Lazy Portfolio.'
p4
aS'SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG ... PR Newswire  - Nov 14, 2016 FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and&nbsp;...'
p5
aS"Why SciClone Pharmaceuticals Is Soaring Today Motley Fool - Nov 10, 2015 So what: SciClone Pharmaceuticals' Zadaxin is an immune stimulating drug that is used to treat hepatitis B. The drug, which isn't available in the United States, is sold primarily in China, which is home to roughly one third of the globe's hepatitis B ..."
p6
aS"SciClone Announces Progress In Advancing Clinical Pipeline For China ... PR Newswire  - Sep 26, 2016 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.  today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China."
p7
aS"Did SciClone Pharmaceuticals Inc  Create Value For Shareholders Over The ... Simply Wall St - Mar 6, 2017 SciClone Pharmaceuticals Inc  delivered a 19.7% ROE over the past year; however, the figure is only significant when we compare it to returns from assets with similar risk profile: the industry average, which stood at 27.38% in the same ...SciClone Pharmaceuticals'  CEO Friedhelm Blobel on Q4 2016 Results ... - Seeking Alpha"
p8
aS'SciClone Pharmaceuticals Inc. SCLN  Wall Street Journal - Feb 12, 2011 News SciClone Pharmaceuticals Inc.SCLN. Significant News Only. 03/06/17; Press Release. SciClone Reports 2016 Financial Results And 2017 Outlook.'
p9
aS"Insider Trading Activity SciClone Pharmaceuticals, Inc.   CEO ... Market Exclusive - Feb 24, 2017 Friedhelm Blobel , CEO of SciClone Pharmaceuticals, Inc.  reportedly Sold 39,177 shares of the company's stock at an average price of 9.83 for a total transaction amount of $385,109.91 SEC Form."
p10
a.